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Pentraxin 3 (PTX3) is an essential component of the humoral arm of innate immunity and belongs, together with the C-reactive
protein (CRP) and other acute phase proteins, to the pentraxins’ superfamily: soluble,multifunctional, pattern recognition proteins.
Pentraxins share a common C-terminal pentraxin domain, which in the case of PTX3 is coupled to an unrelated long N-terminal
domain. PTX3 in humans, like CRP, correlates with surrogate markers of atherosclerosis and is independently associated with the
risk of developing vascular events. Studies addressing the potential physiopathological role of CRP in the cardiovascular systemwere
so far inconclusive and have been limited by the fact that the sequence and regulation have not been conserved during evolution
between mouse and man. On the contrary, the conservation of sequence, gene organization, and regulation of PTX3 supports the
translation of animalmodel findings in humans.While PTX3 deficiency is associatedwith increased inflammation, cardiac damage,
and atherosclerosis, the overexpression limits carotid restenosis after angioplasty. These observations point to a cardiovascular
protective effect of PTX3 potentially associated with the ability of tuning inflammation and favor the hypothesis that the increased
levels of PTX3 in subjects with cardiovascular diseases may reflect a protective physiological mechanism, which correlates with the
immunoinflammatory response observed in several cardiovascular disorders.
1. Introduction
Several inflammatory mediators have been implicated in
the pathogenesis of cardiovascular disorders (CVD) [1] and
most of them, such as the flogistic molecules CD40 and
its soluble ligand, the adhesion molecules ICAM-1, VCAM-
1, E-selectin and P-selectin, the peptides NT-proBNP and
troponin T, and fibrinogen, are useful as systemic biomarkers
for inflammation and tissue damage associated with CVD
[2, 3]. However, the acute phase protein which is widely used
as a biomarker of cardiovascular and inflammatory disorders
is the classical C-reactive protein (CRP), a component of
the pentraxin superfamily [4]. Pentraxins are an essential
component of the humoral arm of innate immunity and are
a superfamily of soluble, multifunctional, pattern recognition
proteins characterized by a cyclic multimeric structure [5, 6].
In addition to CRP, the pentraxin superfamily includes the
long pentraxin 3 (PTX3), a protein composed by a long
characteristic N-terminal domain coupled to the C-terminal
pentraxin domain which is emerging as an important player
in immunity and inflammation [6].The aim of this paper will
be to discuss the experimental and clinical relevance of PTX3
in cardiovascular diseases.
2. The Pentraxin Superfamily
The pentraxin superfamily is characterized by the presence,
in the carboxy-terminal region, of the “pentraxin domain”,
composed of a conserved 8-amino-acid long sequence
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(HxCxS/TWxS, where x is any amino acid) [6]. Pentraxins
are divided into short and long pentraxins based on the
primary structure of the protein: CRP and serum amyloid
P-component (SAP) are two well-characterized short pen-
traxins of about 25-kDa, mainly produced by hepatocytes in
response to proinflammatory mediators, such as IL-6 [6, 7].
In humans, plasma levels of CRP are below 3mg/L under
normal conditions but could increase up to 1000 folds in 48
hours during the acute-phase response; this is not true for
SAP plasma levels which are relatively stable (30–50mg/L)
even during the acute-phase response [6].
PTX3, which is the prototypic long pentraxin, was identi-
fied in the early 1990s, as amolecule rapidly induced by IL-1 in
endothelial cells (ECs) or by tumor necrosis factor (TNF) in
ECs and fibroblast [8, 9]. The protein presents a high degree
of conservation from mouse to human (82% identical and
92% conserved amino acids) and is induced in a variety of
somatic and innate immunity cells by primary inflammatory
stimuli [6]. PTX3 plays a nonredundant role as a soluble
pattern recognition receptor for selected pathogens [10] but
is also critical for extracellular matrix (ECM) deposition,
fertility, and vascular biology [6, 11]. In addition, in humans,
PTX3 plasma levels increase during vascular atherosclerosis,
inflammation, or damage [12] especially after myocardial
infarction and reach the peak much earlier compared to CRP
[13].This prompted the research to investigate whether PTX3
may represent a rapid biomarker for primary local activation
of innate immunity and inflammation [11].
3. PTX3: From Molecular Structure
to Physiological Implications
3.1. Gene Organization, Protein Structure, and Production.
The human PTX3 gene has been localized on chromosome
3 band q25 and is organized in three exons separated by
two introns: the first two encode the signal peptide and the
N-terminal domain of the protein, respectively, whereas the
third exon encodes the C-terminal domain, the pentraxin
sequence with high degree of conservation with short pen-
traxins [8]. The murine gene shows high evolutionary con-
servation in sequence, gene organization and regulation [14].
Indeed, the proximal promoters of both human and murine
PTX3 genes share numerous potential enhancer-binding
elements, including activator protein-1 (AP-1), nuclear factor
kappa B (NF-𝜅B), and selective promoter factor 1 (SP1). It has
been shown that the NF-𝜅B-binding site is essential for the
transcriptional response to pro-inflammatory cytokines, as
TNF-𝛼 and interleukin 1𝛽 (IL-1𝛽), whereas AP-1 controls the
basal transcription of PTX3 [14, 15].
The mature secreted PTX3 protein consists of a major
45 kD form of monomers, which are assembled to form
multimers predominantly of 440 kD apparent molecular
mass [6]. The N-glycosylation site in the C-terminal domain
[16] affects the binding of PTX3 to a number of ligands and
links changes in the glycosylation status with the modulation
of the activity [16].
PTX3 is induced in several cell types, including
ECs, fibroblast, smooth muscle cells (SMCs), adipocytes,
mesangial cells, and synoviocytes, following the exposure to
several inflammatory signals: IL-1𝛽, TNF-𝛼, TRL agonists,
and microbial components, including lipopolysaccharide
(LPS), lipoarabinomannan, outer membrane proteins,
peptidoglycan, and oxidized lipids [8, 9, 17–21]. Also in
myeloid cells, such as monocytes and dendritic cells (DCs),
PTX3 expression is induced by pro-inflammatory stimuli;
polymorphonuclear cells (PMNs) instead do not express
PTX3 messenger RNA [17] but present the protein stored in
specific granules in a ready-to-use form, which is released
in response to microorganisms or TLR agonists [22].
In these cells the protein localizes in extracellular traps
extruded from activated PMNs (neutrophil extracellular
traps) and contribute to the generation of an antimicrobial
microenvironment essential to trapping and killing microbes
[23, 24]. More recently also anti-inflammatory molecule
were shown to modulate PTX3 expression. Glucocorticoid
hormones (GCs) induce and enhance the protein expression
under inflammatory conditions in fibroblast, but not in
myeloid cells [25], while high-density lipoproteins (HDLs),
which possess a series of vascular protective activities
[26], induce PTX3 expression in endothelial cells [27]. The
latter mechanism requires the activation of the PI3K/Akt
pathway through G-coupled lysosphingolipid receptors
and is mimicked by sphingosine 1 phosphate and other
S1P mimetics [27], physiologically present in HDL and
responsible for some of the activities linking HDL to the
immunoinflammatory response [28].
3.2. Multifunctional Properties of PTX3 in Innate Immunity.
PTX3 is a key player of the humoral arm of the innate
immunity and its physiological functions are associated to
the recognition and binding to different ligands, including
microbial moieties, complement components, and P-selectin.
Similarly to short pentraxins, PTX3 recognizes the
highly conserved pathogen-associated molecular patterns
(PAMPs) expressed by microorganisms [29] and binds a
number of bacteria, fungi, and viruses. A specific binding
has been observed to conidia of Aspergillus fumigatus [10],
Paracoccidioides brasiliensis, and zymosan [30], to selected
gram-positive and gram-negative bacteria [10, 18, 31] and
finally to some viral strains, including human and murine
cytomegalovirus and influenza virus type A (IVA) [31, 32].
Both short pentraxin and PTX3 bind apoptotic cells and
facilitate their clearance [33, 34]. Surface boundCRP activates
the classical pathway of complement through interaction
with C1q, thus leading to cells elimination [35]. Cell-bound
PTX3 might favor the clearance of apoptotic cells [34, 36] by
enhancing the deposition of both C1q and C3 on cell surface
[35]. On the contrary, when in the fluid phase, PTX3 interacts
with C1q and dampens the deposition on apoptotic cells and
the resulting phagocytosis by DCs and phagocytes [37–40].
In addition to PTX3 C1q recognizes and binds to ficolin-
2 and mannose-binding lectin (MBL), thus modulating the
classical and the lectin pathways of complement activation
[41]. The best described and characterized ligand of PTX3
is the first component of the classical complement system
C1q [35, 41]; PTX3 interacts with the globular head of
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the protein [42] thus resulting in the activation of the classical
complement cascade only when C1q is plastic-immobilized,
a situation that mimics C1q bound to a microbial sur-
face. On the contrary, when the interaction occurs in the
fluid phase, a dose-dependent inhibition of C1q haemolytic
activity is observed, suggesting a possible inhibitory effect
by competitive blocking of relevant site [35]. A further
level of modulation of complement activation by PTX3 is
dependent on the glycosylation status of the protein; indeed,
deglycosylation or desialylation enhance PTX3 binding to
C1q, because of a reduction of the dissociation rate which
stabilizes the PTX3/C1q complex [16]. PTX3 interacts with
ficolin-2 [43] and the MBL [44], thus promoting also the
activity of the lectin-dependent complement pathway and
favors complement deposition on A. fumigatus conidia and
opsonophagocytosis of Candida albicans by polymorphonu-
clear leucocytes [45]. Of note, PTX3 interacts also with
Factor H [46] and C4b-binding protein (C4BP) [33, 47], two
inhibitors of the complement cascade, thus probably favoring
a negative feedback, limiting an exaggerated complement
activation. Recently, it has been shown that PTX3 competes
with leukocyte PSGL-1 for the interaction with P-selectin
through the binding of the N-linked glycosidic moiety in the
C-terminal domain of PTX3. This mechanism was shown, in
vivo, to inhibit the rolling of leukocytes on P-selectin and
to limit P-selectin-dependent inflammation by dampening
excessive neutrophil recruitment and extravasation [48].
4. PTX3: An Emerging Player in
Cardiovascular Diseases
In the last decade, the presence of PTX3 was detected in the
myocardium and in the vasculature under different patho-
logical conditions which was paralleled by the observation of
increased plasma PTX3 levels in patients with cardiovascular
disorders [12]. These data prompted the research toward the
investigation of the role of PTX3 as biomarker, player, or
both in the context of cardiovascular disease. So far a role
for PTX3 was described in the context of angiogenesis, vas-
cular restenosis, atherosclerosis, and myocardial infarction
(Figure 1).
4.1. Role of PTX3 in Angiogenesis and Restenosis. PTX3
dampens fibroblast-growth-factor-2-(FGF2-) dependent ECs
proliferation [49] in vitro and this results in the inhibition
of angiogenesis, the process of new blood vessel formation
[50–52]. Transfection of PTX3 in normal microvascular
endothelial cells (MVECs) blunts their angiogenic properties,
while PTX3 silencing by small interfering RNA restores
the ability of the cells to produce capillaries and promotes
angiogenesis [53].
This effect is dependent on the ability of PTX3 to bind
with high affinity and selectivity FGF-2 [51, 54] which in
turn results in the inhibition of the interaction of FGF2
with tyrosine-kinase receptors (FGFRs) and heparin sulphate
proteoglycans (HSPGs) on the surface of ECs and SMCs,
thus dampening the generation of the proangiogenic complex
HSPG/FGF2/FGFR [20].
Interestingly, TSG6, the secreted product of tumor necro-
sis factor-stimulated gene, reverts the inhibitory effects
exerted by PTX3 on FGF2-dependent angiogenesis through
competition with FGF2/PTX3 interaction, thus exerting a
proangiogenic function [55]. The interaction between TSG-
6 and the N-terminal domain of PTX3 plays also a funda-
mental role in female fertility: TSG-6, the glycosaminoglycan
hyaluronan (HA), inter-𝛼-trypsin inhibitor (I𝛼I), and PTX3
all cooperate in the formation of an ECM around the
preovulatory oocyte, the cumulus oophorus complex (COC)
matrix [56, 57].These interactions are essential for the correct
organization of the viscoelastic matrix of cumulus oophorus
and the lack of PTX3 is associated with female subfertility, as
a consequence of cumulus matrix instability [58, 59].
The FGF/FGFR system plays also a crucial role in SMC
proliferation, migration, and survival in vitro [60–63] and
neointimal thickening after arterial injury in vivo [64, 65].
These processes are critically involved in restenosis, the
process of blood vessel narrowing that frequently occurs
after percutaneous transluminal coronary angioplasty of
atherosclerotic arteries. The possibility that PTX3, by inter-
acting with FGF2, could inhibit FGF2-dependent SMCs acti-
vation and intimal thickening after carotid injury is indeed
intriguing. Experimental data confirmed this hypothesis and
the overexpression of PTX3 in vivo or exogenously added
PTX3 in vitro resulted in the inhibition of FGF2-dependent
SMCs proliferation [54]. This effect was associated with
the suppression of the mitogenic and chemotactic activities
exerted by endogenous FGF2 on these, sequestering the
growth factor in an inactive form [54].
These observations suggest that PTX3 could act as an
“FGF2 decoy” and may represent a potent inhibitor of the
autocrine and paracrine stimulations exerted by FGF2 on
SMCs and point to a novel therapeutic role of PTX3 in the
treatment of restenosis after angioplasty [45].
4.2. PTX3 and Atherosclerosis. Immunohistochemical stain-
ing of advanced atherosclerotic lesions revealed a strong
expression of PTX3 on the surface of lumen as well as
within the atherosclerotic plaque in animal models and in
humans [66, 67]. Cholesterol accumulation in the intima
of the vessels, the major pathological feature of atheroscle-
rosis, is associated with the induction of an immune-
inflammatory response resulting in the recruitment ofmono-
cyte/macrophages, PMNs and in the activation of ECs, which
are all able to produce PTX3 in response to inflamma-
tory stimuli normally associated with atherogenesis. IL-1
and TNF𝛼 are both expressed in advance atherosclerotic
lesions [68–70] and these molecules are major candidates
for regulating PTX3 expression [67]. Moreover, it has been
demonstrated that the disruption of the internal layers of
the vessel, after coronary stenting in patients with severe
atherosclerosis, causes the increase of PTX3 plasma lev-
els already after 15 minutes [71]. Furthermore, neutrophils
and monocytes/macrophages could contribute to the large
amount of PTX3 observed in arterial thrombi and aortic
tissue in patientswith different degrees of atherosclerosiswith
acute myocardial infarction [72].
4 Mediators of Inflammation
PTX3
Protective functions
Cardio inflammatory state
PTX3 deficiency
↓ FGF2 activity ↓ P-selectin function
↑
↑
↑
↑
↑
↑
↑
Atherosclerosis
↑ Heart damage and inﬂammation
Myocardial lesions
Atherosclerotic lesions
Macrophage accumulation
Tissue damage with a greater no-reﬂow area
SMCs proliferation and migration
Intimal thickening after arterial injury
Restenosis
Neutrophil and macrophage infiltration
Bone marrow monocytosis
↓
↓
↓
↓
↓
↓
Recruitment and extravasation of leukocytes
Platelet prothrombotic action
Tissue damage and inﬂammation
Figure 1: Effects of PTX3 in cardiovascular diseases. PTX3 plasma levels rapidly increase during atherosclerosis andMI in humans andmice.
PTX3 could then interact with FGF2 and/or P-selectin and exert cardiovascular protective activities. On the contrary, PTX3 deficiency leads
to increased heart damage and inflammation after MI and atherosclerosis.
Oxidized LDL (but not native LDL) increases PTX3
mRNA expression in vascular SMCs (VSMCs), an effect
dependent on NF-𝜅B activation [21]. In turn, PTX3 could
favor the clearance of lipid-loaded macrophages and VSMCs
apoptotic cells mediating their removal by mature DCs [21].
A similar effect could rely on the atheroprotective activity of
HDL that was shown to induce PTX3 expression [28] and
potentially promote the same mechanism [73].
The potential role of PTX3 in atherosclerosis was recently
addressed in PTX3/apolipoprotein E (ApoE) double knock-
out mice [66]. Normally mice are poorly susceptible to
atherosclerosis [74]; therefore, the effects of the deficiency or
the overexpressions of a protein have to be tested inmice with
a background susceptible to atherosclerosis. For this reason,
specific transgenic mice were generated and among them,
mice lacking apoE or LDL-receptor are widely used [74–76].
PTX3 KO/Apo E KO mice developed larger atheroscle-
rotic lesions compared to Apo E KO, an observation
that was coupled to increased macrophage accumulation,
increased bone marrow monocytosis, and, interestingly,
increased expression of adhesion molecules, cytokines, and
chemokines in the vascular wall. These findings suggest an
increased immune-inflammatory response in PTX3 KO/Apo
E KO mice compared to Apo E KO animals [66].
PTX3 expression, similar to that of CRP, is increased
also in coronary plaques of patients with unstable angina
pectoris (UAP) compared to those with stable angina (SAP).
Nevertheless, PTX3 and CRP distribution is different; PTX3
expression is increased in complicated plaque compared to
fibroatheroma, while the opposite is true for CRP; moreover
abundant PTX3 was detected in intraplaque hemorrhage,
while CRP stainingwasmore intense in lipid rich plaque [77].
Finally PTX3 is highly expressed in CD163-positive areas
which normally marks anti-inflammatory M2 macrophages
[77].
In summary, PTX3 is produced following stimulation of
macrophages, SMCs, and ECs with LPS, IL-1, TNF, or oxLDL
and is able to induce tissue factor [78, 79]. Functional data
clearly point to a cardiovascular protective effect [12] which is
associated with the ability to dampen ischemic heart disease
and atherosclerosis.
4.3. PTX3 in Ischemic Heart Disease. Plasma concentration
of PTX3 rapidly rises in the early phase after ischemic heart
disorders in humans and animal models [13, 67, 80, 81]
suggesting the possibility that PTX3 could also play a role
in myocardial infarction. To this aim coronary artery ligation
and reperfusion was performed in PTX3-deficient mice [81].
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Following myocardial infarction, increased PTX3 mRNA
and protein expression was observed in the ischemic area
of the heart. PTX3 KO mice had greater myocardial lesions,
an increased tissue damage with a greater no-reflow area,
increased neutrophil and macrophage infiltration, decreased
number of capillaries, and increased number of apoptotic
cardiomyocytes, a phenotype reversed by the use of exoge-
nous PTX3 [81]. The possibility that PTX3 could dampen
an excessive complement system activation is supported by
the observation that C3 deposition is increased in infarct
areas of PTX3 KO mice [81]. Of note, in the intestinal
ischemia/reperfusion model, obtained by the total occlu-
sion of the superior mesenteric artery, Souza and col-
leagues showed that PTX3 overexpression is associated with
increased cytokines production, tissue inflammation, and a
reduced survival [82]. This finding was later confirmed in
PTX3 KO mice which showed an opposite profile [83].
These works clearly highlight different roles played by
PTX3 in mediating reperfusion injury in the heart, where its
function is protective and localized, rather than the intestine,
where PTX3 has a harmful role [83] and could also indicate
that the molecule may have different functions in different
settings or temporal windows of vascular pathology.
More recently, the identification of P-selectin as a target
protein of PTX3 [48] raised the possibility that this mech-
anism could be relevant in disorders where the excessive
neutrophil recruitment to activated endothelium and collat-
eral damages associated to leukocyte activation such as acute
coronary syndromes could play a role [84].
Maugeri and colleagues identified PTX3 stored in neu-
trophils’ secondary granules as an attractive candidate that
leads to the increased plasma levels of the protein after early
AMI [85].The depletion of neutrophil intracellular PTX3was
also associated with increased platelets-neutrophil aggregates
and with the binding between PTX3 and activated platelets,
which dampens their inflammatory potential and prothrom-
botic action [85]. Future studies should investigate whether
PTX3might exert a protective role in AMI by dampening the
neutrophil-activation loop during atherothrombosis.
5. PTX3: A Clinical Biomarker
of Cardiovascular Inflammation
Following myocardial infarction (MI), PTX3 plasma levels
peak within 7.5 hours as compared to CRP which peaks
around 50 hours [13]. In MI patients, PTX3 but not CRP,
after adjustment for major risk factors and other acute phase
proteins, independently predicted 3-month mortality [80].
These data, suggesting PTX3 as a strong prognosticmarker of
CVD death, paved the road for several studies addressing its
role as a biomarker of cardiovascular inflammation (Figure 2)
independently of other acute phase proteins such as CRP.
5.1. PTX3 in Subclinical Atherosclerosis and Peripheral Vascu-
lar Diseases. Ultrasound detection and quantification of the
common carotid artery wall thickness (intima-media thick-
ness, IMT) (CCA-IMT) is considered a surrogate marker of
subclinical atherosclerosis [86].
In the Bruneck study, PTX3 plasma levels, although not
correlated with CCA-IMT, were higher in individuals with
atherosclerotic plaques and prevalent vascular diseases [87].
Also in patients with metabolic syndrome, PTX3 levels
were directly correlated with CCA-IMT [88]; this correlation,
however, was no longer significant after adjustment for HDL-
C levels. As not only PTX3 but also HDL sense changes in the
immune response [89], the possibility that, in patients with
metabolic syndrome, changes in PTX3 orHDL-C levels could
both reflect similar alterations in the immunoinflammatory
profile should not be excluded. The analysis of the predictive
value of PTX3 levels on IMT progression, in addition to the
association with IMT, is warranted to support the relevance
of PTX3 as a marker of preclinical atherosclerosis.
PTX3 levels, together with proteinuria, were also shown
to be independently associated with endothelial dysfunction
in end-stage renal disease patients [90]; this suggests the
possibility that PTX3 could also represent a biomarker
of peripheral vascular damage. Studies investigating PTX3
levels in relation to arterial stiffness, peripheral artery disease
(PAD), or pulse wave velocity (PWV) are warranted to clarify
this issue.
5.2. PTX3 in Acute Coronary Syndromes. PTX3 is present in
the intactmyocardium, increases in the blood of patients with
acute myocardial infarction, and represent an early indicator
of myocytes irreversible injury in ischemic cardiomyopathy
[13].
In a large cohort of patients with myocardial infarction,
with ST elevation, PTX3 but not the liver-derived short
pentraxin CRP or other cardiac biomarkers (NT-proBNP,
TnT, CK) predicted 3-month mortality after adjustment for
major risk factors and other acute-phase prognostic markers
[80]. Of note, ECG-documented postinfarction angina, re-
infarction, or induced ischemia after the provocative test
was not affected by this marker. A similar observation was
confirmed in the Cardiovascular Health Study where PTX3
was showed to be independently associated with increased
risk of all-cause death and cardiovascular-disease-(CVD-)
related mortality (also after adjusting for all major cardio-
metabolic risk factors) [91]. Further studies confirmed that
PTX3 represents a more specific marker for acute coronary
syndrome (ACS) compared to neutrophil activating peptide-
2 (NAP-2) and cardiac troponin I (cTnI) in patients with
unstable angina pectoris, NSTEMI, and STEMI within the
first six hours of the onset of chest pain [92]; furthermore
its coronary sinus plasma levels positively correlate with
the Gensini score and negatively with multidetector-row
computed tomography plaque density (while hsCRP did not)
[93]. These findings support the concept of PTX3 as a very
sensitive marker of plaque inflammation and vulnerability
and of the prognosis of the coronary disease.
Patients with unstable angina pectoris and those who
undergo percutaneous coronary intervention generally
present PTX3 levels three times higher than the reference
range [94]. Coronary stenting enhances circulating PTX3
levels in association with an inflammatory response and
the levels are positively correlated with the increase in
6 Mediators of Inflammation
PTX3
Plasma levels
Vascular damage
Intima-media thickness (IMT)
Percutaneous coronary intervention (PCI)
Restenosis
Neutrophils
Endothelial cells
Vascular smooth muscle cells
Cardiac inflammatory disorders
Heart failure
Myocardial infarction
Atrial fibrillation
Macrophages
Figure 2: PTX3 as a marker of cardiovascular inflammation. A variety of cell types produce PTX3 in response to pro- and anti-inflammatory
signals. Increased PTX3 levels are useful as a marker of different cardiovascular diseases including (a) cardiac inflammatory disorders, such
as HF, MI, and atrial fibrillation, and (b) vascular damage, as IMT, PCI, and restenosis.
activated Mac-1 on the surface of neutrophils at 48 h in the
coronary sinus [71]. These data suggest that PTX3 may be a
useful marker for evaluation of inflammatory reaction and
neointimal thickening after coronary vascular injury and
also myocardial infarction.
5.3. PTX3 in Heart Failure. The role of inflammation in
the progression of chronic heart failure (HF) is debated.
Among the different markers of inflammation tested PTX3
was consistently associated with outcomes in HF patients
[95]. In two large independent clinical trials (CORONA and
GISSI-HF), baseline elevated PTX3 was associated with a
higher risk of all-cause mortality cardiovascular mortality or
hospitalization for worsening HF. Three-month changes in
PTX3 were associated with fatal events after adjustment for
hsCRP or NT-proBNP [95].
PTX3 levels were positively associated with the severity of
dilatative cardiomyopathy and increased risk of HF [96]. Fur-
thermore high PTX3 plasma levels (but not CRP, interleukin-
6, or TNF-𝛼) were associated with an echocardiographic
measure of left ventricular dysfunction (E/𝑒󸀠 ratio) in controls
without HF and in patients with HF and normal or reduced
ejection fraction [97]. PTX3 levels were significantly elevated
in patients with HF but normal ejection fraction (HFNEF)
and the protein was observed in the coronary circulation in
patients with left ventricular diastolic dysfunction (LVDD)
[97] indicating that PTX3, but not high-sensitivity CRP, is
an independent inflammatory marker correlated with the
presence of LVDD and HFNEF.
The clinical application of assessing blood PTX3 for
predicting HF development is debated [98] and studies
addressing how PTX3 would compare with established HF
markers, such as B-type natriuretic peptide, are warranted.
6. Conclusions
PTX3 has emerged as a key acute-phase protein associated
with inflammation in cardiovascular disorders, including
heart failure, atherosclerosis, acute coronary syndromes, and
peripheral vascular diseases. More importantly the predictive
value of PTX3 appears to be independent of other risk
factors including other markers of the same superfamily such
as CRP. The rapid increase of PTX3 plasma levels during
cardiovascular events as a consequence of rapid synthesis
by various cell types supports the idea that PTX3 could be
an early indicator of the activation of both immune and
inflammatory responses.
Data from animalmodels suggest that this increasemight
reflect a feedback mechanism involved in dampening an
excessive inflammation rather than only the consequence
of the activation of the immunoinflammatory system. The
ability of PTX3 to control infections and subsequent inflam-
mation will fit with this hypothesis [10, 48].
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In conclusion, available data indicate PTX3 as a potential
target for therapy. While rosuvastatin was shown to increase
PTX3 levels in patients with HF this activity was not associ-
ated with a beneficial effect [95]. On the contrary pitavastatin
treatment was associated with reduced PTX3 levels [99]. The
pharmacological relevance of targeting PTX3 in relation to
clinical benefits would represent therefore a main subject of
investigation for further studies.
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